Gemina Laboratories Ltd.
GLABF
$0.77
$0.03384.59%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.28% | -18.79% | -2.42% | 41.55% | 44.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -31.47% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.19% | -44.92% | -38.93% | -15.36% | 9.88% |
| Operating Income | 42.19% | 44.92% | 38.93% | 15.36% | -9.77% |
| Income Before Tax | 47.27% | 43.44% | 38.16% | 15.06% | -14.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.27% | 43.44% | 38.16% | 15.06% | -14.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.27% | 43.44% | 38.16% | 15.06% | -14.99% |
| EBIT | 42.19% | 44.92% | 38.93% | 15.36% | -9.77% |
| EBITDA | 42.32% | 45.12% | 39.10% | 15.50% | -9.80% |
| EPS Basic | 50.44% | 48.26% | 47.02% | 29.08% | 4.34% |
| Normalized Basic EPS | 50.70% | 48.55% | 46.99% | 29.09% | 4.25% |
| EPS Diluted | 50.44% | 48.26% | 47.02% | 29.08% | 4.34% |
| Normalized Diluted EPS | 50.70% | 48.55% | 46.99% | 29.09% | 4.25% |
| Average Basic Shares Outstanding | 5.54% | 9.22% | 15.77% | 21.12% | 21.42% |
| Average Diluted Shares Outstanding | 5.54% | 9.22% | 15.77% | 21.12% | 21.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
